Skip to content

Investing in Our People: Career Development at Scailyte

Investing in Our People: Career Development at Scailyte

Investing in Our People: Career Development at Scailyte

Investing in Our People: Career Development at Scailyte

At Scailyte, our commitment to nurturing talent and fostering professional growth is evident. We believe that investing in our people is not just good for business, but it’s the right thing to do. Our dedication to career development shines through in several ways:

Performance Reviews: All our teammates undergo a performance review at least annually. This process helps Scailyters understand their strengths, discuss how to nurture them with their line manager and identify areas for improvement. This process also supports the alignment of teammates goals with our organizational objectives.

Individual Development Plans: We recognize that each team member is empowered to lead his/her career trajectory in a unique manner. That’s why all teammates have individual development plans in place. These tailored roadmaps support our Scailyters on their journey towards personal and professional growth.

Skills Development Training: We’re dedicated to equipping our team with the skills they need to excel. Through skills development training, we ensure that our teammates are not just keeping pace with industry trends but also leading the way.

Continuous Learning: Our commitment to growth extends to a comprehensive program that encompasses meticulous onboarding, diverse on-the-job training opportunities, active involvement in business decisions, leadership role assignments, peer training, structured mentoring, and coaching relationships. It’s all part of our mission to empower every Scailyte team member for success.

Thank you to our amazing team for making Scailyte a place where talent is nurtured, careers are built, and futures are bright. Stay tuned for more updates on our commitment to career development!

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte Extends Series A to USD 8 Million

We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...

Read more

Recent News

ScaiDigest Volume 6: Variational autoencoders (VAEs) in biology

Welcome to the 6th edition of ScaiDigest, where we explore cutting-edge research in single-cell anal...

Read more

Recent News

Pitch-nic Expo

We're excited to share that our Senior Vice President of Corporate & Technology Development, Corinne...

Read more

Recent News

Targets & Cell Types in Immuno-Oncology Europe 2023

Scailyte is part of Targets & Cell Types in Immuno-Oncology Europe 2023 event on November 14-15 in B...

Read more

Recent News

Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs

We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...

Read more

Recent News

NextGen Omics 2023

Scailyte is gearing up for NextGen Omics 2023, one of the most scientifically engaging events in Lon...

Read more

Recent News

SITC 2023

Diana Stoycheva and Julian Spagnuolo will be sharing Scailyte’s science at a poster #201, and will...

Read more

Recent News

ScaiDigest Volume 5: Unlocking the Secrets of AML

Read Diana's insightful post and stay at the forefront of scientific advancements in the field!

Read more

Recent News

01 /04

Scailyte Extends Series A to USD 8 Million

We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...

Read more

ScaiDigest Volume 6: Variational autoencoders (VAEs) in biology

Welcome to the 6th edition of ScaiDigest, where we explore cutting-edge research in single-cell anal...

Read more

Recent News

02 /04

Pitch-nic Expo

We're excited to share that our Senior Vice President of Corporate & Technology Development, Corinne...

Read more

Targets & Cell Types in Immuno-Oncology Europe 2023

Scailyte is part of Targets & Cell Types in Immuno-Oncology Europe 2023 event on November 14-15 in B...

Read more

Recent News

03 /04

Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs

We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...

Read more

NextGen Omics 2023

Scailyte is gearing up for NextGen Omics 2023, one of the most scientifically engaging events in Lon...

Read more

Recent News

04 /04

SITC 2023

Diana Stoycheva and Julian Spagnuolo will be sharing Scailyte’s science at a poster #201, and will...

Read more

ScaiDigest Volume 5: Unlocking the Secrets of AML

Read Diana's insightful post and stay at the forefront of scientific advancements in the field!

Read more

Recent News